ArticleNeurology2023
Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg.
Open access · hybridAbstract read
In one paragraph
Article in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
13.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Kidney Function and Blood and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Related Dementias: Systematic Review and Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2026Pooled it
- Effect of 6-week tadalafil treatment on blood-based biomarkers of neurodegeneration: A post-hoc analysis of a randomized controlled trial.Journal of Alzheimer's disease : JAD · 2026Trial
- Can non-pharmacological interventions change levels of neurofilament light in older adults at risk of dementia? A secondary analysis of the SCD-Well randomized clinical trial.The journal of prevention of Alzheimer's disease · 2025Trial
- Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's disease.Alzheimer's research & therapy · 2025Trial
- Article
- Brain pathology in relation to somatic diseases: Exploring the body-brain crosstalk.Journal of internal medicine · 2026Review
- Late-onset severe axonal polyneuropathy in mut0 methylmalonic acidemia after liver-kidney transplantation: a genotype-informed case report.BMC neurology · 2026Article
- Neurofilament Light Chain and Cognitive Dysfunction in Patients Undergoing Hemodialysis: A Cross-Sectional Exploratory Study.Kidney360 · 2026Article
- Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Dynamic patterns of anemia and cognitive function: a longitudinal cohort study based on the China Health and Retirement Longitudinal Study.BMC public health · 2026Article
- Quantifying brain-age gap in people with HIV on antiretroviral therapy using plasma neurofilament light chain.AIDS (London, England) · 2026Article
- Generalizability of blood-based biomarkers of Alzheimer's disease and related dementias in a multicultural cohort of older adults: The effect of adjustment for kidney function.Journal of Alzheimer's disease : JAD · 2026Article
- Association of plasma p-tau and p-tau/Aβ ratio with Alzheimer's pathology.The journal of prevention of Alzheimer's disease · 2026Article
- Blood-based biomarkers for Alzheimer's disease: influence of kidney function.Alzheimer's research & therapy · 2026Article
- Kidney Function, Alzheimer Disease Blood Biomarkers, and Dementia Risk in Community-Dwelling Older Adults.Neurology · 2026Article
- Chronic Kidney disease and cognitive frailty in aging: molecular crosstalk and clinical implications.Frontiers in aging neuroscience · 2026Review
- Health-related factors and their impact on blood-based biomarkers of Alzheimer's disease.Aging brain · 2026Article
- Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Prognostic Value of A/T/N Biomarkers: Comparing Plasma and Imaging Modalities in Alzheimer Disease.Clinical nuclear medicine · 2025Article
- Impact of kidney function on biomarkers of neurodegeneration, white matter hyperintensities, and cognition in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 4 countries.
Anna DittrichFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden. anna.dittrich@vgregion.se.
Nicholas J AshtonFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.ORCID 0000-0002-3579-8804
Henrik ZetterbergFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.ORCID 0000-0002-4671-6763
Kaj BlennowFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.ORCID 0000-0002-1890-4193
Anna ZettergrenFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.
Joel SimrénFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.ORCID 0000-0001-5081-6604
Tobias SkillbäckFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.
Sara ShamsFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.
Alejandra MachadoFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.
Eric WestmanFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.ORCID 0000-0002-3115-2977
Michael SchöllFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.ORCID 0000-0001-7800-1781
Ingmar SkoogFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.
Silke KernFrom the Neuropsychiatric Epidemiology Unit (A.D., A.Z., T.S., I.S., S.K.), Sahlgrenska Academy, University of Gothenburg; Department of Psychiatry Cognition and Old Age Psychiatry (A.D., I.S., S.K.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (N.J.A., H.Z., K.B., J.S., M.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal Campus, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), London, UK; Centre for Age-Related Medicine (N.J.A.), Stavanger University Hospital, Norway; Clinical Neurochemistry Laboratory (H.Z., K.B., J.S.), Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL (H.Z.); Department of Neurodegenerative Disease (H.Z., M.S.), UCL Institute of Neurology, London, UK; Hong Kong Center for Neurodegenerative Diseases (H.Z.), China; Care Sciences and Society (S.S.), Karolinska Institutet, and Department of Radiology; Department of Clinical Neuroscience (S.S.), Karolinska University Hospital, Stockholm, Sweden; Department of Radiology (S.S.), Stanford University, CA; Division of Clinical Geriatrics (A.M., E.W.), Department of Neurobiology, Care Sciences and Society (NVS), Karolinska University Hospital; Division of Insurance Medicine (A.M.), Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging (E.W.), Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; and Wallenberg Center of Molecular and Translational Medicine (M.S.), University of Gothenburg, Sweden.
Sahlgrenska University Hospital · SEKarolinska University Hospital · SEStavanger University Hospital · NO
Funding
The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normalR01AG068398 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIANG, GLORIA CHIA-YI · 2020 to 2024
$2.8MNIA NIH HHS R01 AG068398
Abstract
BACKGROUND AND
objectivesStudies associate chronic kidney disease (CKD) with neurodegeneration. This study investigated the relationship between kidney function, blood, CSF, and structural brain MRI markers of neurodegeneration in a sample including individuals with and without CKD.
methodsParticipants from the Gothenburg H70 Birth Cohort Study, with data on plasma neurofilament light (P-NfL), estimated glomerular filtration rate (eGFR), and structural brain MRI were included. Participants were invited to also have the CSF collected. The primary endpoint of this study was to determine any association between CKD and P-NfL. Secondary endpoints included cross-sectional associations between CKD, eGFR, and CSF-derived and MRI-derived markers of neurodegeneration and Alzheimer disease (AD) pathology (MRI: cortical thickness, hippocampal volume, lateral ventricle volume, and white matter lesion volume; CSF: β-amyloid (Aβ) 42, Aβ42/40, Aβ42/p-tau, t-tau, p-tau, and NfL). Participants with P-NfL and eGFR at baseline were re-examined on eGFR, 5.5 (5.3-6.1) years (median; IQR) after the first visit, and the predictive value of P-NfL levels on incident CKD was estimated longitudinally, using a Cox proportional hazards model.
resultsWe included 744 participants, 668 without CKD (age 71 [70-71] years, 50% males) and 76 with CKD (age 71 [70-71] years, 39% males). Biomarkers from the CSF were analyzed in 313 participants. A total of 558 individuals returned for a re-examination of eGFR (75% response rate, age 76 [76; 77] years, 48% males, 76 new cases of CKD). Participants with CKD had higher P-NfL levels than those with normal kidney function (median; 18.8 vs 14.1 pg/mL, DISCUSSION: In a community-based cohort of 70-year olds, P-NfL was associated with both prevalent and incident CKD, while CSF and/or imaging measures did not differ by CKD status. Participants with CKD and dementia presented similar levels of P-NfL.
Indexed as
Alzheimer DiseaseNeurofilament ProteinsAgedAmyloid beta-PeptidesBiomarkersCohort StudiesCross-Sectional StudiesFemaleHumansMaletau ProteinsAmyloid beta-PeptidesBiomarkersNeurofilament Proteinstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.